Javascript must be enabled to continue!
The Effects of Personalized Dietary Intervention on Hypertensive Patients: A Randomized Control Trial in Jieshou
View through CrossRef
Abstract
Background
To design a personalized dietary intervention package for hypertensive patients (PDIPH) and to assess its impact on the patient’s blood pressure and knowledge-attitude-practice (KAP) score.
Methods
A randomized controlled trial of 3,005 hypertensive patients from JieShou City were recruited and used the iFLYTEK intelligent voice sphygmomanometer. After excluding unqualified patients, there were 1,190 and 1,202 patients randomly divided into intervention and control groups respectively. Patients in the control group received the same health care as the intervention group, with the exception of PDIPH. The intervention period was from 15 August 2021 to 15 February 2022. The difference in blood pressure, knowledge, attitude, and behavior (KAP) scores between the 2 groups before and after the intervention was evaluated. Blood pressure values were assessed for all patients in both groups, and KAP scores were assessed for a total of 529 patients randomly selected from the 2 groups.
Results
At the 6th month, the systolic blood pressure and diastolic blood pressure decreased by (9.11 ± 18.76) and (3.26 ± 12.50) mm Hg, respectively in the intervention group, while it decreased by (5.71 ± 17.63) and (2.15 ± 12.76) mm Hg, respectively in the control group. There was a significant difference in the decrease of systolic blood pressure between the 2 groups (t = 5.554, P < 0.05). After 6 months of intervention, the increases in KAP score of the intervention group were higher than that of the control group (P < 0.05). A multivariable linear regression model showed that the difference in eating behavior scores was positively correlated with systolic blood pressure difference (β = 0.19, P = 0.024) and BMI had the greatest positive effect on diastolic blood pressure difference (β = 0.20, P = 0.034).
Conclusions
In hypertensive patients, PDIPH could reduce patients’ blood pressure levels and improve their KAP scores.
Oxford University Press (OUP)
Title: The Effects of Personalized Dietary Intervention on Hypertensive Patients: A Randomized Control Trial in Jieshou
Description:
Abstract
Background
To design a personalized dietary intervention package for hypertensive patients (PDIPH) and to assess its impact on the patient’s blood pressure and knowledge-attitude-practice (KAP) score.
Methods
A randomized controlled trial of 3,005 hypertensive patients from JieShou City were recruited and used the iFLYTEK intelligent voice sphygmomanometer.
After excluding unqualified patients, there were 1,190 and 1,202 patients randomly divided into intervention and control groups respectively.
Patients in the control group received the same health care as the intervention group, with the exception of PDIPH.
The intervention period was from 15 August 2021 to 15 February 2022.
The difference in blood pressure, knowledge, attitude, and behavior (KAP) scores between the 2 groups before and after the intervention was evaluated.
Blood pressure values were assessed for all patients in both groups, and KAP scores were assessed for a total of 529 patients randomly selected from the 2 groups.
Results
At the 6th month, the systolic blood pressure and diastolic blood pressure decreased by (9.
11 ± 18.
76) and (3.
26 ± 12.
50) mm Hg, respectively in the intervention group, while it decreased by (5.
71 ± 17.
63) and (2.
15 ± 12.
76) mm Hg, respectively in the control group.
There was a significant difference in the decrease of systolic blood pressure between the 2 groups (t = 5.
554, P < 0.
05).
After 6 months of intervention, the increases in KAP score of the intervention group were higher than that of the control group (P < 0.
05).
A multivariable linear regression model showed that the difference in eating behavior scores was positively correlated with systolic blood pressure difference (β = 0.
19, P = 0.
024) and BMI had the greatest positive effect on diastolic blood pressure difference (β = 0.
20, P = 0.
034).
Conclusions
In hypertensive patients, PDIPH could reduce patients’ blood pressure levels and improve their KAP scores.
Related Results
RESEARCH ON THE RE-DESIGN APPLICATION OF “JIESHOU” COLORED
RESEARCH ON THE RE-DESIGN APPLICATION OF “JIESHOU” COLORED
ABSTRACT
To explore the application strategy of “JieShou” pottery decoration elements in modern cultural and creative production design, to protect the inheritance and development...
Small Cell Lung Cancer and Tarlatamab: A Meta-Analysis of Clinical Trials
Small Cell Lung Cancer and Tarlatamab: A Meta-Analysis of Clinical Trials
Abstract
Introduction
Tarlatamab is a Delta-like ligand 3 (DLL3) -directed bispecific T-cell engager recently approved for use in patients with advanced small cell lung cancer (SCL...
International Breast Cancer Study Group (IBCSG)
International Breast Cancer Study Group (IBCSG)
This section provides current contact details and a summary of recent or ongoing clinical trials being coordinated by International Breast Cancer Study Group (IBCSG). Clinical tria...
HYPERTENSIVE CRISES: HYPERTENSIVE EMERGENCY AND CRISIS MANAGEMENT DURING ANESTHESIA
HYPERTENSIVE CRISES: HYPERTENSIVE EMERGENCY AND CRISIS MANAGEMENT DURING ANESTHESIA
Introduction: hypertensive crisis is characterized by an acute and massive increase in blood pressure. Hypertensive crises encompass several clinical situations with different seve...
Spanish Breast Cancer Research Group (GEICAM)
Spanish Breast Cancer Research Group (GEICAM)
This section provides current contact details and a summary of recent or ongoing clinical trials being coordinated by Spanish Breast Cancer Research Group (GEICAM). Clinical trials...
A Comparative Change in Left Ventricular Mass Index on Echocardiography in Hypertensive Diabetic and Non-Diabetic Patients Taking Candesartan
A Comparative Change in Left Ventricular Mass Index on Echocardiography in Hypertensive Diabetic and Non-Diabetic Patients Taking Candesartan
Background: To assess the evolution of the left ventricular mass index on echocardiography in candesartan-treated hypertension individuals with and without diabetes. Study Design: ...
Metabolic syndrome in hypertensive and non‐hypertensive subjects
Metabolic syndrome in hypertensive and non‐hypertensive subjects
AbstractBackground and aimsHypertension is a major risk factor of cardiovascular diseases (CVDs), which attributes to one‐third of all deaths worldwide. It is also considered as a ...
Pharmacogenomics and the Concept of Personalized Medicine for the Management of Hypertension
Pharmacogenomics and the Concept of Personalized Medicine for the Management of Hypertension
Hypertension poses a significant global burden due to low adherence to antihypertensive medications. Hypertension treatment aims to bring blood pressure within physiological ranges...

